Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-11-01
2005-11-01
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000
Reexamination Certificate
active
06960566
ABSTRACT:
Compositions containing one or more peptido-mimetics or modified peptido-mimetics of a carbohydrate ligand of an adhesion molecule in a physiologically acceptable carrier are useful for methods of reducing metastasis in a mammal and for inhibiting inflammatory response in a mammal. Particularly useful are embodiments in which the ligand is a Lewis antigen and/or the adhesion molecule is a selectin, e.g, E-selectin. Methods are disclosed for identifying peptido-mimetics of carbohydrate ligands, which may be involved in binding of tumor cells to other cells, such as endothelial cells.
REFERENCES:
patent: 5464935 (1995-11-01), Heavner et al.
patent: 5602230 (1997-02-01), Heavner et al.
patent: 5614615 (1997-03-01), Wong
patent: 5618785 (1997-04-01), Heavner et al.
patent: 5639734 (1997-06-01), Esko et al.
patent: 5643873 (1997-07-01), Barrett et al.
patent: 5861505 (1999-01-01), Kern
patent: 2003/0017497 (2003-01-01), Keiber-Emmons et al.
MJ Polley, ML Phillips, E Wayner, E Nudelman, AK Singhal, S Hakomori, and JC Paulson CD62 and Endothelial Cell-Leukocyte Adhesion Molecule 1 (ELAM-1) Recognize the Same Carbohydrate Ligand, Sialyl-Lewis x PNAS 1991 88: 6224-6228.
R. Radinsky et al, “Regulation of Tumor Cell Growth at Organ Specific Metastases”, in vivo, 6:325-332 (1992).
G. Nicolson, “Metastatic Tumor Cell Interactions with Endothelium, Basement Membrane and Tissue”, Current Opinion in Cell Biology, 1:1009-1019 (1989).
M. Bevilacqua et al, “Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins”, Science, 243:1160-1165 (Mar., 1989).
P. Brodt, “Adhesion Receptors and Proteolytic Mechanisms in Cancer Invasion and Metastasis”, in Cell Adhesion and Invasion in Cancer Metastasis, ed. by P. Brodt, Chapter 11, pp. 167-242 (1996).
E. Butcher et al, “Lymphocyte Homing and Homeostasis”, Science, 272:60-66 (Apr., 1996).
L. Lasky, “Selectin-Carbohydrate Interactions and the Initiation of the Inflammatory Response”, Annu. Rev. Biochem., 64:113-139 (1995).
A. Varki, “Selectin Ligands”, Proc. Natl. Acad. Sci. USA, 91:7390-7397 (Aug., 1994).
M. Bevilacqua et al, “Selectins”, J. Clin. Invest., 91:379-387 (Feb., 1993).
G. Mannori et al, “Differential Colon Cancer Cell Adhesion to E-, P-, and L-selectin: Role of Mucin-type Glycoproteins”, Cancer Research, 55:4425-4431 (Oct., 1995).
S. Karpatkin et al, “Role of Platelets in Tumor Cell Metastases”, Annals of Internal Medicine, 95:636-641 (Nov., 1981).
D. Welch et al, “Tumor-elicited Polymorphonuclear Cells, in Contrast to ‘Normal’ Circulating Polymorphonuclear Cells, Stimulate Invasive and Metastatic Potentials of Rat Mammary Adenocarcinoma Cells”, Proc. Natl. Acad. Sci. USA, 86:5859-5863 (Aug., 1989).
A. Seth et al, “T-Cell-Receptor-Independent Activation of Cytolytic Activity of Cytotoxic T Lymphocytes Mediated Through CD44 and gp90MEL-14”, Proc. Natl. Acad. Sci. USA, 88:7877-7881 (Sep., 1991).
F. Kolbinger et al, “The Carbohydrate-Recognition Domain of E-Selectin is Sufficient for Ligand Binding Under Both Static and Flow Conditions”, Biochemistry. 35:6385-6392 (1996).
B. Revelle et al, “Single Amino Acid Residues in the E- and P-selectin Epidermal Growth Factor Domains Can Determine Carbohydrate Binding Specificity”, J. Biol. Chem., 271(27):16160-16170 (Jul., 1996).
S. Li et al, “Consensus Repeat Domains of E-selectin Enhance Ligand Binding”, J. Biol. Chem, 269(6):4431-4437 (Feb., 1994).
D. Erbe et al, “P- and E-Selectin Use Common Sites for Carbohydrate Ligand Recognition and Cell Adhesion”, J. Cell Biol., 120(5):1227-1235 (Mar., 1993).
B. Graves et al, “Insight into E-selectin/ligand Interaction from the Crystal Structure and Mutagenesis of the lec/EGF Domains”, Nature, 367:532-538 (Feb., 1994).
R. Giavazzi et al, “Rolling and Adhesion of Human Tumor Cells on Vascular Endothelium under Physiological Flow Conditions”, J. Clin. Invest., 92:3038-3044 (Dec., 1993).
E. Dejana et al, “Endothelial Leukocyte Adhesion Molecule-1-Dependent Adhesion of Colon Carcinoma Cells to Vascular Endothelium is Inhibited by an Antibody to Lewis Fucosylated Type I Carbohydrate Chain”, Laboratory Investigation, 66(3):324-330 (1992).
A. Takada et al, “Contribution of Carbohydrate Antigens Sialyl Lewis A and Sialyl Lewis X to Adhesion of Human Cancer Cells to Vascular Endothelium”, Cancer Research, 53:354-361 (Jan., 1993).
R. Sawada et al, “Differential E-selectin-dependent Adhesion Efficiency in Sublines of a Human Colon Cancer Exhibiting Distinct Metastatic Potentials”, J. Biol. Chem., 269(2):1425-1431 (Jan., 1994).
P. Brodt et al, “Liver Endothelial E-Selectin Mediates Carcinoma Cell Adhesion and Promotes Liver Metastasis”, Int. J. Cancer, 71:612-619 (1997).
G. Mannori et al, “Inhibition of Colon Carcinoma Cell Lung Colony Formation by a Soluble Form of E-Selectin”, American Journal of Pathology 151(1):233-243 (Jul., 1997).
L. Biancone et al, “Redirection of Tumor Metastasis by Expression of E-Selectin in Vivo”, J. Exp. Med., 183:581-587 (Feb., 1996).
K. Iwai et al, “Importance of E-Selectin (ELAM-1) and Sialyl Lewisain the Adhesion of Pancreatic Carcinoma Cells to Activated Endothelium”, Int. J. Cancer, 54:972-977 (1993).
A. Tözeren et al, “E-Selectin-Mediated Dynamic Interactions of Breast- and Colon-Cancer Cells with Endothelial-Cell Monolayers”, Int. J. Cancer, 60:426-431 (1995).
M. Miyake et al, “Correlation of Expression of H/Lev/LebAntigens with Survival in Patients with Carcinoma of the Lung”, N. Engl. J. Med., 327:14-18 (Jul., 1992).
J. Garrigues et al, “Anti-Tumor Antibody BR96 Blocks Cell Migration and Binds to a Lysosomal Membrane Glycoprotein on Cell Surface Microspikes and Ruffled Membranes”, J. Cell Biol., 125(1):129-142 (Apr., 1994).
G. Kansas, “Selectins and Their Ligands: Current Concepts and Controversies”, Blood, 88(9):3259-3287 (Nov., 1996).
D. Ingber et al, “Mechanochemical Switching Between Growth and Differentiation During Fibroblast Growth Factor-Stimulated Angiogenesis in Vitro: Role of Extracellular Matrix”, J. Cell. Biol., 109:317-330 (Jul., 1989).
M. Nguyen et al, “1-Deoxymannojirimycin Inhibits Capillary Tube Formation in Vitro”, J. Biol. Chem., 267(36):26157-26165 (Dec., 1992).
J. Folkman, “Clinical Applications of Research on Angiogenesis”, N. Engl. J. Med., 333(26):1757-1763 (Dec., 1995).
M. Agadjanyan et al, “Peptide Mimicry of Carbohydrate Epitopes on Human Immunodeficiency Virus”, Nature Biotechnology 15:547-551 (Jun., 1997).
T. Tsukida et al, “Studies on Selectin Blockers. 7. Structure-Activity Relationships of Sialyl Lewis X Mimetics Based on Modified Ser-Glu Dipeptides”, J. Med. Chem., 41:4279-4287 (1998).
D. Ishikawa et al, “GD1α-replica Peptides Functionally Mimic CG1α, an Adhesion Molecule of Metastatic Tumor Cells, and Suppress the Tumor Metastasis”, FEBS Letters, 441:20-24 (1998).
Bechtel et al., “Conformational analysis of the tumor-associated carbohydrate antigen 19-9 and its Lea blood group antigen component as related to the specificity of monoclonal antibody CO19-9”,J. Biol. Chem.Feb. 5, 1990 265(4):2028-2037.
Blaszczyk et al., “Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related antigens defined by monoclonal antibodies”,Cancer Res.Jan. 1984 44(1):245-253.
Blaszczyk et al., “Characterization of Lewis antigens in normal colon and gastrointestinal adenocarcinomas”,Proc. Natl. Acad. Sci. USAJun. 1985 82(11):3552-3556.
Blaszczyk et al., “Lewis blood group antigens defined by monoclonal anti-colon carcinoma antibodies”,Arch. Biochem. Biophys.
Howson and Howson
The Trustees of the University of Pennsylvania
The Wister Institute of Anatomy and Biology
LandOfFree
Compositions and methods for treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3507337